© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
COMPETITION TRIGGERS PRICE CUTS, FDA FINDS
Fresh evidence of the power of generic drugs toreduce US health costs surfaced as part of a newFDA study that documents the sharp declines inprescription drug prices following the onset ofgeneric competition. According to the analysis,much of the downward pressure on Rx price levelsoccurs after 2 generic versions reach the market.
When a brand name drug faces only one genericcompetitor, the discount associated with that singlegeneric averages only 6% of the branded drug'sprice. The FDA, however, found that as additionalgenerics reach the market, prices begin to fall dramatically.When a second generic manufacturerlaunches its product, the average per-dose price forthe generic medication falls to 52% of the brandname version's cost.
Prices continue to decline as more generic competitorsenter the market. According to the FDAanalysis, when 9 generic versions become available,these products sell for an average of just 20%of the price of the brand name product. The FDA'sanalysis was based on 1999-2004 retail sales dataon single-ingredient drug products collected by IMSHealth Inc.